The complement system is one of the most important weapons of innate immunity and is involved in all infectious processes. It is not only a mechanism for direct protection against an invading pathogen but it also interacts with the adaptive immunity to optimize the pathogen-specific humoral and cellular defence cascade in the body. One of the greatest challenges for the complement system is infection by HIV with its chronic course and sequential destruction of immune cells and immune organs. Due to its dual role as direct effector and as fine tuner of adaptive immunity, we focussed on complement in this review and analysed in detail the contribution of complement to the antiviral defence and to HIV pathogenesis on the one hand and the complement evasion strategies of the virus on the other hand. In the present review, this interplay between complement and the virus is illuminated for the three different stages of HIV pathogenesis and for events during therapy: (1) the acute infection process with the early events in mucosa and serum; (2) the asymptomatic stage with the complex interplay between complement-induced lysis and viral evasion strategies; (3) the symptomatic infection and AIDS stage with progressive destruction of the lymph nodes, opportunistic infections and development of neuropathogenesis, and (4) finally, during highly active antiretroviral therapy and in vaccination approaches.

1.
Speth C, Würzner R, Stoiber H, Dierich MP: The complement system: Pathophysiology and clinical relevance. Wien Klin Wochenschr 1999;111:378–391.
2.
Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H: Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. J Immunol 2002;169:3301–3306.
3.
Lehner T, Bergmeier L, Wang Y, Tao L, Mitchell E: A rational basis for mucosal vaccination against HIV infection. Immunol Rev 1999;170:183–196.
4.
Hussain LA, Kelly C, Rodin A, Jourdan M, Lehner T: Investigation of the complement receptor 3 (CD11b/CD18) in human rectal epithelium. Clin Exp Immunol 1995;102:384–388.
5.
Bomsel M, David V: Mucosal gatekeepers: Selecting HIV viruses for early infection. Nat Med 2002;8:114–116.
6.
Veazey RS, Marx PA, Lackner AA: The mucosal immune system: Primary target for HIV infection and AIDS. Trends Immunol 2001;22:626–633.
7.
Cranage MP, Baskerville A, Ashworth LAE, Dennis M, Cook N, Cook R, Sharpe SA, Rose J, Kitchin P, Greenaway PJ: Mucosal infection and vaccine studies with macaque SIV. Vaccine Res 1992;1:311–318.
8.
Lehner T, Wang Y, Cranage M, Bergmeier L, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle C, Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996;2:767–775.
9.
Prodinger WM, Würzner R, Stoiber H, Dierich MP: Complement; in Paul WE (ed): Fundamental Immunology. Lippincott-Raven.
10.
Vanderpuye OA, Labarrere CA, McIntyre JA: The complement system in human reproduction. Am J Reprod Immunol 1992;27:145–155.
11.
Stoiber H, Kacani L, Speth C, Würzner R, Dierich MP: The supportive role of complement in HIV pathogenesis. Immunol Rev 2001;180:168–176.
12.
Saifuddin M, Landay AL, Ghassemi M, Patki C, Spear GT: HTLV-I activates complement leading to increased binding to complement receptor-positive cells. AIDS Res Hum Retroviruses 1995;11:1115–1122.
13.
Stoiber H, Clivio A, Dierich MP: Role of complement in HIV infection. Annu Rev Immunol 1997;15:649–674.
14.
Spear GT, Jiang HX, Sullivan BL, Gewurz H, Landay AL, Lint TF: Direct binding of complement component C1q to human immunodeficiency virus (HIV) and human T lymphotrophic virus-I (HTLV-I) coinfected cells. AIDS Res Hum Retroviruses 1991;7:579–585.
15.
Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP: Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991;174:1417–1424.
16.
Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, Kumar C: Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996;271:20231–20234.
17.
Gerard NP, Gerard C: The chemotactic receptor for human C5a anaphylatoxin. Nature 1991;349:614–617.
18.
Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, Götze O: Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992;79:152–160.
19.
Kacani L, Bánki Z, Zwirner J, Schennach H, Baytay Z, Erdei A, Stoiber H, Dierich MP: C5a and C5adesArg enhance the susceptibility of monocyte-derived macrophages to HIV infection. J Immunol 2000;166:3410–3415.
20.
Merrill JE, Koyanagi Y, Chen IS: Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989;63:4404–4408.
21.
Griffin GE, Leung K, Folks TM, Kunkel S, Nabel GJ: Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature 1989;339:70–73.
22.
Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK: Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994;68:8001–8007.
23.
Cooper NR, Jensen FC, Welsh RM Jr, Oldstone MB: Lysis of RNA tumor viruses by human serum: Direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976;144:970–984.
24.
Bartholomew RM, Esser AF: Differences in activation of human and guinea pig complement by retroviruses. J Immunol 1978;121:1748–1751.
25.
Bartholomew RM, Esser AF, Muller-Eberhard HJ: Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E. J Exp Med 1978;147:844–853.
26.
Sherwin SA, Benveniste RE, Todaro GJ: Complement-mediated lysis of type-C virus: Effect of primate and human sera on various retroviruses. Int J Cancer 1978;21:6–11.
27.
Jensen FC: Inactivation and lysis of oncornaviruses by human and primate complement. Haematol Blood Transfus 1979;23:501–503.
28.
Kobilinsky L, Hardy WD Jr, Ellis R, Witkin SS, Day NK: In vitro activation of feline complement by feline leukemia virus. Infect Immun 1980;29:165–170.
29.
Dierich MP, Stoiber H, Chen Y-H: HIV and complement; in Gupta S (ed): Immunology of HIV infection. New York, Plenum, 1996, pp 365–376.
30.
Sullivan BL, Knopoff EJ, Saiffudin M, Takefman DM, Saarloos MN, Sha BE, Spear GT: Susceptibility of HIV-1 plasma virus to complement-mediated lysis. J Immunol 1996;157:1791–1798.
31.
Dierich MP, Stoiber H, Clivio A: A ‘complement-ary’ AIDS vaccine. Nat Med 1996;2:153–155.
32.
Takefman DM, Sullivan BL, Sha BE, Spear GT: Mechanisms of resistance of HIV-1 primary isolates to complement-mediated lysis. Virology 1998;46:370–378.
33.
Spear GT, Lurain NS, Parker CJ, Ghassemi M, Payne GH, Saifuddin M: Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV). J Immunol 1995;155:4376–4381.
34.
Spear GT, Sullivan BL, Takefman DM, Landay AL, Lint TF: Human immunodeficiency virus (HIV)-infected cells and free virus directly activate the classical complement pathway in rabbit, mouse and guinea-pig sera; activation results in virus neutralization by virolysis. Immunology 1991;73:377–382.
35.
Saifuddin M, Parker CJ, Peeples ME, Gorny MK, Zolla-Pazner S, Ghassemi M, Rooney IA, Atkinson JP, Spear GT: Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med 1995;182:501–509.
36.
Schmitz J, Zimmer JP, Kluxen B, Aries S, Bogel M, Gigli I, Schmitz H: Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59. J Clin Invest 1995;96:1520–1526.
37.
Frank I, Stoiber H, Godar S, Möst J, Stockinger H, Dierich MP: Acquisition of host cell-surface-derived molecules by HIV-1. AIDS 1996;10:1611–1620.
38.
Montefiori DC, Cornell RJ, Zhou JY, Zhou JT, Hirsch VM, Johnson PR: Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 1994;205:82–92.
39.
Marschang P, Sodroski J, Würzner R, Dierich MP: Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur J Immunol 1995;25:285–290.
40.
Stoiber H, Pintér C, Siccardi AG, Clivio A, Dierich MP: Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55). J Exp Med 1996;183:307–310.
41.
Stoiber H, Ammann C, Spruth M, Müllauer B, Eberhart A, Harris CL, Huber CG, Longhi R, Falkensammer B, Würzner R, Dierich MP: Enhancement of complement-mediated lysis by a peptide derived from SCR13 of complement factor H. Immunobiology 2001;203:670–686.
42.
Reisinger EC, Vogetseder W, Berzow D, Kofler D, Bitterlich G, Lehr HA, Wachter H, Dierich MP: Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell line U937. AIDS 1990;4:961–965.
43.
Thieblemont N, Haeffner-Cavaillon N, Haeffner A, Cholley B, Weiss L, Kazatchkine MD: Triggering of complement receptors CR1 (CD35) and CR3 (CD11b/CD18) induces nuclear translocation of NF-kappa B (p50/p65) in human monocytes and enhances viral replication in HIV-infected monocytic cells. J Immunol 1995;155:4861–4867.
44.
June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT: Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 1991;5:269–274.
45.
Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996;173:60–67.
46.
Robinson WE Jr, Montefiori DC, Mitchell WM: Complement-mediated antibody-dependent enhancement of HIV-1 infection requires CD4 and complement receptors. Virology 1990;175:600–604.
47.
Robinson WE Jr, Montefiori DC, Mitchell WM: Will antibody-dependent enhancement of HIV-1 infection be a problem with AIDS vaccines? Lancet 1988;1:830–831.
48.
Gras GS, Dormont D: Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol 1991;65:541–545.
49.
Tremblay M, Meloche S, Sekaly RP, Wainberg MA: Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells. J Exp Med 1990;171:1791–1796.
50.
Gras G, Richard Y, Roques P, Olivier R, Dormont D: Complement and virus-specific antibody-dependent infection of normal B lymphocytes by human immunodeficiency virus type 1. Blood 1993;81:1808–1818.
51.
Delibrias CC, Mouhoub A, Fischer E, Kazatchkine MD: CR1(CD35) and CR2(CD21) complement C3 receptors are expressed on normal human thymocytes and mediate infection of thymocytes with opsonized human immunodeficiency virus. Eur J Immunol 1994;24:2784–2788.
52.
Toth FD, Mosborg-Petersen P, Kiss J, Aboagye-Mathiesen G, Zdravkovic M, Hager H, Aranyosi J, Lampe L, Ebbesen P: Antibody-dependent enhancement of HIV-1 infection in human term syncytiotrophoblast cells cultured in vitro. Clin Exp Immunol 1994;96:389–394.
53.
Boyer V, Delibrias C, Noraz N, Fischer E, Kazatchkine MD, Desgranges C: Complement receptor type 2 mediates infection of the human CD4-negative Raji B-cell line with opsonized HIV. Scand J Immunol 1992;36:879–883.
54.
Boyer V, Desgranges C, Trabaud MA, Fischer E, Kazatchkine MD: Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion. J Exp Med 1991;173:1151–1158.
55.
Brack-Werner R: Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 1999;13:1–22.
56.
Hess C, Klimkait T, Schlapbach L, Del Zenero V, Sadallah S, Horakova E, Balestra G, Werder V, Schaefer C, Battegay M, Schifferli JA: Association of a pool of HIV-1 with erythrocytes in vivo: A cohort study. Lancet 2002;359:2230–2234.
57.
Zhou J, Montefiori DC: Complement-activating antibodies in sera from infected individuals and vaccinated volunteers that target human immunodeficiency virus type 1 to complement receptor type 1 (CR1, CD35). Virology 1996;226:13–21.
58.
Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, Meese E, Wain-Hobson S, Meyerhans A: Multiply infected spleen cells in HIV patients. Nature 2002;418:144.
59.
Montefiori DC, Graham BS, Zhou JY, Zhou JT, Ahearn JM: Binding of human immunodeficiency virus type 1 to the C3b/C4b receptor CR1 (CD35) and red blood cells in the presence of envelope-specific antibodies and complement. National Institutes of Health AIDS Vaccine Clinical Trials Networks. J Infect Dis 1994;170:429–432.
60.
Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang ZQ, Dailey PJ, Balfour HH Jr, Erice A, Perelson AS: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996;274:985–989.
61.
Cohen JH, Geffriaud C, Caudwell V, Kazatchkine MD: Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. AIDS 1989;3:397–399.
62.
Jouvin MH, Rozenbaum W, Russo R, Kazatchkine MD: Decreased expression of the C3b/C4b complement receptor (CR1) in AIDS and AIDS-related syndromes correlates with clinical subpopulations of patients with HIV infection. AIDS 1987;1:89–94.
63.
Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, Baseler M, Ehler LA, Liu S, Davey RT Jr, Mican JA, Fauci AS: B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med 2000;192:637–646.
64.
Doepper S, Stoiber H, Kacani L, Sprinzl G, Steindl F, Prodinger WM, Dierich MP: B cell-mediated infection of stimulated and unstimulated autologous T lymphocytes with HIV-1:Role of complement. Immunobiology 2000;202:293–305.
65.
Jakubik JJ, Saifuddin M, Takefman DM, Spear GT: Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J Virol 2000;74:552–555.
66.
Jakubik JJ, Saifuddin M, Takefman DM, Spear GT: B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. Immunology 1999;96:612–619.
67.
Kacani L, Prodinger WM, Sprinzl GM, Schwendinger MG, Spruth M, Stoiber H, Dopper S, Steinhuber S, Steindl F, Dierich MP: Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J Virol 2000;74:7997–8002.
68.
Joling P, Bakker LJ, Van Strijp JA, Meerloo T, de Graaf L, Dekker ME, Goudsmit J, Verhoef J, Schuurman HJ: Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol 1993;150:1065–1073.
69.
Haase AT: Population biology of HIV-1 infection: Viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999;17:625–656.
70.
Pantaleo G, Cohen OJ, Schacker T, Vaccarezza M, Graziosi C, Rizzardi GP, Kahn J, Fox CH, Schnittman SM, Schwartz DH, Corey L, Fauci AS: Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy. Nat Med 1998;4:341–345.
71.
Reynes M, Aubert JP, Cohen JH, Audouin J, Tricottet V, Diebold J, Kazatchkine MD: Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2687–2694.
72.
Szakal AK, Kosco MH, Tew JG: Microanatomy of lymphoid tissue during the induction and maintenance of humoral immune responses: Structure function relationships. Annu Rev Immunol 1989;7:91–109.
73.
Koopman G, Haaksma AG, ten Velden J, Hack CE, Heeney JL: The relative resistance of HIV type 1-infected chimpanzees to AIDS correlates with the maintenance of follicular architecture and the absence of infiltration by CD8+ cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 1999;15:365–373.
74.
Heath SL, Tew JG, Tew JG, Szakal AK, Burton GF: Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995;377:740–744.
75.
Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605–1613.
76.
Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831–837.
77.
Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, Wood KC, Holmberg SD: Influence of co-infection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;36:363–367.
78.
Kittlesen DJ, Chianese-Bullock KA, Yao ZQ, Braciale TJ, Hahn YS: Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J Clin Invest 2000;106:1239–1249.
79.
Spiller OB, Robinson M, O’Donnell E, Milligan S, Morgan BP, Davison AJ, Blackbourn DJ: Complement regulation by Kaposi’s sarcoma-associated herpesvirus ORF4 protein. J Virol 2003;77:592–599.
80.
Spiller OB, Blackbourn DJ, Mark L, Proctor DG, Blom AM: Functional activity of the complement regulator encoded by Kaposi’s sarcoma associated herpes virus. J Biol Chem, in press.
81.
Würzner R: Evasion of pathogens by avoiding recognition or eradication by complement, in part via molecular mimicry. Mol Immunol 1999;36:249–260.
82.
Janulczyk R, Ianelli F, Sjoholm AG, Pozzi G, Bjorck L: Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 2000;275:37257–37263.
83.
Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Bjorck L, Meri S: Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8–11 of factor H. J Immunol 2002;168:1886–1894.
84.
Duthy TG, Ormsby RJ, Giannakis E, Ogunniyi AD, Stroeher UH, Paton JC, Gordon DL: The human complement regulator factor H binds pneumococcal surface protein PspC via short consensus repeats 13 to 15. Infect Immun 2002;70:5604–5611.
85.
Denning DW: Invasive aspergillosis. J Infect Dis 1998;26:781–805.
86.
Washburn RG, Hammer CH, Bennett JE: Inhibition of complement by culture supernatants of Aspergillus fumigatus. J Infect Dis 1986;154:944–951.
87.
Washburn RG, DeHart DJ, Agwu DE, Bryant-Varela BJ, Julian NC: Aspergillus fumigatus complement inhibitor: Production, characterization, and purification by hydrophobic interaction and thin-layer chromatography. Infect Immun 1990;58:3508–3515.
88.
Henwick S, Hetherington SV, Patrick CC: Complement binding to Aspergillus conidia correlates with pathogenicity. J Lab Clin Med 1993;122:27–35.
89.
Fabry Z, Raine CS, Hart MN: Nervous tissue as an immune compartment: The dialect of the immune-response in the CNS. Immunol Today 1994;15:218–224.
90.
Speth C, Stöckl G, Mohsenipour I, Würzner R, Stoiber H, Lass-Flörl C, Dierich MP: Human immunodeficiency virus type 1 induces expression of complement factors in human astrocytes. J Virol 2001;75:2604–2615.
91.
Speth C, Schabetsberger T, Mohsenipour I, Stöckl I, Würzner R, Stoiber H, Lass-Flörl C, Dierich MP: Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol 2002;76:3179–3188.
92.
Jongen PJH, Doersburg WH, Ibrahim-Stappers JLM, Lemmens WAJG, Hommes OR, Lamers KJB: Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system. Acta Neurol Scand 2000;101:116–121.
93.
Farkas I, Baranyi L, Takahashi M, Fukuda A, Liposits Z, Yamamoto T, Okada H: A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J Physiol 1998;507:679–687.
94.
Farkas I, Baranyi L, Liposits ZS, Yamamoto T, Okada H: Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience 1998;86:903–911.
95.
Osaka H, Mukherjee P, Aisen PS, Pasinetti GM: C-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999;73:303–311.
96.
Speth C, Dierich MP, Gasque P: Neuroinvasion by pathogens: A key role of the complement system. Mol Immunol 2002;38:669–679.
97.
Spear GT, Olinger G, Sullivan BL, Landay AL, Kessler H: Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons. AIDS Res Hum Retroviruses 1999;15:1713–1715.
98.
Stiegler G, Armbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, Jagodzinski LL, Ammann C, Jäger W, Jacobson J, Vetter N, Katinger H: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: A phase I evaluation. AIDS 2002;16:2019–2025.
99.
Stoiber H, Frank I, Spruth M, Schwendinger M, Mullauer B, Windisch JM, Schneider R, Katinger H, Ando I, Dierich MP: Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): An accessory role for CR3 during virus entry? Mol Immunol 1997;34:855–863.
100.
Pinter C, Beltrami S, Stoiber H, Negri DRM, Titti F, Clivio A: Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection. Expert Opin Investig Drugs 2000;9:199–205.
101.
Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978–3991.
102.
Wang B, Boyer JD, Ugen KE, Srikantan V, Ayyaroo V, Agadjanyan MG: Nucleic acid-based immunisation against HIV-1: Induction of protective in vivo immune responses. AIDS 1995;9:S159–S170.
103.
Wang B, Boyer J, Srikantan V, Ugen K, Agadjanian M, Merva M: DNA inoculation induces cross clade anti-HIV-1 responses. Ann NY Acad Sci 1995;772:186–197.
104.
Boyer JD, Wang B, Ugen KE, Agadjanyan M, Javadian A, Frost P, Dang K, Carrano RA, Ciccarelli R, Coney L, Williams WV, Weiner DB: In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol 1996;25:242–250.
105.
Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K: Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology 2001;103:98–105.
106.
Green TD, Montefiori DC, Ross TM: Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. J Virol 2003;77:2046–2055.
107.
Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL: Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001;17:829–835.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.